

REMARKS

Claims 10-20 and 22-38 are pending in the present application. Claims 10-19 have been rejected. Claims 10-19 have been canceled. The Applicants acknowledge and thank the Examiner for recognizing the patentability of Claims 20 and 22-38.

I. Rejection of Claims 10-19 under 35 U.S.C. 112, second paragraph

Claims 10-19 have been rejected under 35 U.S.C. 112, second paragraph, as being indefinite for allegedly failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Without acquiescing to this rejection, claims 10-19 have been canceled and thus the rejections are moot.

II. Rejection of Claims 10-17 under 35 U.S.C. 112, first paragraph

Claims 10-17 have been rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the written description requirement.

Without acquiescing to this rejection, claims 10-17 have been canceled and thus the rejections are moot.

III. Rejection of Claims 10, 11 and 18 under 35 U.S.C. 112, first paragraph

Claims 10, 11 and 18 have been rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to comply with the enablement requirement.

Without acquiescing to this rejection, claims 10, 11 and 18 have been canceled and thus the rejections are moot.


IV. Allowance of Claims 20 and 22-38

The Applicants thank the Examiner for recognizing the patentability of Claims 20 and 22-38.

V. Conclusion

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, she is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,



Philip B. Polster, II

Attorney for Applicants
Reg. No. 43,864
PHARMACIA CORPORATION
Corporate Patent Law Department
314-274-9094 (St. Louis)